Related Experiment Video
Updated: Oct 26, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer
Jun Shiihara1, Fumiyoshi Ohyanagi1,2, Hikari Amari1
1Division of Respiratory Medicine, Clinical Department of Internal Medicine, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Abstract:
Lung cancers with anaplastic lymphoma kinase (ALK) rearrangements are highly sensitive to treatment with ALK tyrosine kinase inhibitors (TKIs). Due to the very low rate of patients with squamous cell carcinoma enrolled in clinical trials, the efficacy of ALK inhibitors in patients with ALK-rearranged squamous cell carcinoma in the lung remains unclear. Herein, we present the case of a 70-year-old female patient with squamous cell lung cancer harboring the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene. The patient was treated with the ALK-TKI alectinib as first-line regimen and achieved a dramatic response without severe adverse events, demonstrating alectinib as a therapeutic option for patients with ALK-positive squamous cell carcinoma.
Insights
Anaplastic lymphoma kinase (ALK) positive squamous cell lung cancer patients can benefit from alectinib treatment. This ALK tyrosine kinase inhibitor (TKI) demonstrated significant efficacy and safety in a patient with this rare cancer subtype.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Anaplastic lymphoma kinase (ALK) rearrangements define a subset of lung cancers sensitive to ALK tyrosine kinase inhibitors (TKIs).
- The efficacy of ALK inhibitors in ALK-rearranged squamous cell carcinoma (SCC) of the lung is not well-established due to limited clinical trial data in this specific histology.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
